A Response to: Letter to the Editor Regarding “Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance”

Bogdan Batko ¹

Jose L. Rivas ²

Faculty of Medicine and Health Sciences, Department of Rheumatology and Immunology, Andrzej Frycz Modrzewski University, Kraków, Poland

Pfizer SLU, Madrid, Spain |

Publication type: Journal Article

Publication date: 2025-01-20

Springer Nature

Journal: Rheumatology and Therapy

scimago Q2

wos Q2

SJR: 1.071

CiteScore: 6.0

Impact factor: 2.9

ISSN: 21986576, 21986584

DOI: 10.1007/s40744-024-00739-1

Copy DOI

Found

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST | RIS | BibTex

Found error?

Publisher

Springer Nature

Journal

scimago Q2

wos Q2

SJR

1.071

CiteScore

6.0

Impact factor

2.9

ISSN

21986576 (Print)

21986584 (Electronic)